Clinical Trials Logo

B-Cell Lymphoma clinical trials

View clinical trials related to B-Cell Lymphoma.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT04418141 Completed - Clinical trials for Advanced Solid Tumor

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1

Start date: July 2, 2020
Phase: Phase 1
Study type: Interventional

This study is the first-in-human clinical trial of CN1 to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma. This study will provide a basis for further clinical development of CN1.

NCT ID: NCT04313608 Completed - B-cell Lymphoma Clinical Trials

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Start date: June 4, 2020
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the safety and efficacy of glofitamab or mosunetuzumab in combination with gemcitabine and oxaliplatin (Glofit-GemOx or Mosun-GemOx) in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL).

NCT ID: NCT04260932 Completed - B-cell Lymphoma Clinical Trials

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients

Start date: March 1, 2020
Phase: Phase 1
Study type: Interventional

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory and relapsed B-cell lymphoma.

NCT ID: NCT04213469 Completed - B-cell Lymphoma Clinical Trials

PD1-CD19-CART in Patients With r/r B-cell Lymphoma

Start date: March 13, 2020
Phase: N/A
Study type: Interventional

This is an open label, single-site, dose-escalation study in up to 25 participants with relapse/refractory B-NHL. This study aims to evaluate the safety and efficacy of the treatment with PD1-CD19-CART.

NCT ID: NCT04036019 Completed - B Cell Lymphoma Clinical Trials

A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

Start date: August 20, 2019
Phase: Phase 1
Study type: Interventional

This is a single-center, non-randomized clinical study to evaluate the safety and efficacy of C-CAR066 in treatment of r/r B cell lymphoma who received CD19 CAR-T therapy.

NCT ID: NCT03804996 Completed - B-Cell Lymphoma Clinical Trials

Study of TG-1801 in Subjects With B-Cell Lymphoma

Start date: March 5, 2019
Phase: Phase 1
Study type: Interventional

Phase 1 first in human Study to Assess the Bispecific Antibody TG-1801 in Subjects with B-Cell Lymphoma

NCT ID: NCT03761056 Completed - B-cell Lymphoma Clinical Trials

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

ZUMA-12
Start date: January 29, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in participants with high-risk large B-cell lymphoma. After the end of KTE-C19-112 (ZUMA-12), participants who received an infusion of axicabtagene ciloleucel will complete the remainder of the 15-year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968.

NCT ID: NCT03734601 Completed - Clinical trials for Acute Myeloid Leukemia

Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation

Start date: November 5, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether addition of a low dose of total body irradiation (TBI) to a standard preparation for transplant [total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG)] conditioning will help to augment donor chimerism without reducing tolerability of this regimen or increasing the risk of graft-vs-host disease (GVHD)

NCT ID: NCT03424603 Completed - Multiple Myeloma Clinical Trials

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Start date: February 22, 2018
Phase: Phase 1
Study type: Interventional

First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.

NCT ID: NCT03424122 Completed - B-cell Lymphoma Clinical Trials

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Start date: July 2, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of parsaclisib when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or refractory B-cell lymphoma.